A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
NCT06500429 on ClinicalTrials.gov · last registry update 2025-09-04
Finished 4 September 2024, after enrolling 120 people. Primary outcome, as filed: Duration of GI-related adverse events. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Neurogastrx, Inc.
- Sponsor type
- Industry
- Enrollment
- 120
- Started
- 2024-06-24
- Primary completion
- 2024-09-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Duration of GI-related adverse events
Conditions studied
Overweight and Obesity · Healthy
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.